ChesneyEGoodwinGMFazelS.Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry. 2014;13:153–160.
2.
FazelSWolfAPalmCViolent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: A 38-year total population study in Sweden. Lancet Psychiatry. 2014;1:44–54.
3.
CrumpCSundquistKWinklebyMAComorbidities and mortality in bipolar disorder: A Swedish national cohort study. JAMA Psychiatry. 2013;70:931–939.
4.
IfteniPCorrellCUBurteaVSudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. Schizophr Res. 2014;155:72–76.
5.
ZivinKYosefMMillerEMAssociations between depression and all-cause and cause-specific risk of death: A retrospective cohort study in the Veterans Health Administration. J Psychosom Res. 2015;78(4):324–331.
ChungAKChuaSE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis. J Psychopharmacol. 2011;25:646–666.
8.
NgFMammenOKWiltingIThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11:559–595.
9.
TaylorDPatonCKapurS.The Maudsley Prescribing Guidelines in Psychiatry. 11th ed.Chinchester (GB): John Wiley & Sons; 2012.
10.
De HertMCohenDBobesJPhysical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138–151.
11.
RamanujPP. Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications. Ment Health Fam Med. 2013;10:29–36.
12.
GilmerTPDolderCRFolsomDPAntipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatr Serv. 2007;58:1007–1010.
13.
NielsenJle QuachPEmborgC10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010;122:356–366.
14.
TsutsumiCUchidaHSuzukiTThe evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective. Schizophr Res. 2011;130:40–46.
15.
YoshioT.[The trend for megadose polypharmacy in antipsychotic pharmacotherapy: A prescription survey conducted by the psychiatric clinical pharmacy research group]. Jpn J Psychiatry Neurol. 2012;114:690–695. Japanese.
16.
XiangYTWangCYSiTMAntipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry. 2012;45:7–12.
17.
YathamLNKennedySHParikhSVCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord. 2013;15:1–44.
18.
FleischhackerWWUchidaH.Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17:1083–1093.
19.
RabkinSW. Impact of age and sex on QT prolongation in patients receiving psychotropics. Can J Psychiatry. 2015;60(5):206–214.
20.
TakeuchiHSuzukiTRemingtonGAntipsychotic polypharmacy and corrected QT interval: A systematic review. Can J Psychiatry. 2015;60(5):215–222.
21.
RotermannMSanmartinCHennessyDPrescription medication use by Canadians aged 6 to 79. Health Rep. 2014;25(6):3–9.
